DoH Policies screened during the period: 1 January 2024 – 31 March 2024

In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.

Documents

Policy proposals that will underpin the Adoption Support Services (Transitional Arrangements) Regulations (Northern Ireland)
PDF (856 KB)

Consent for Hospital Post-Mortem Examination (PME) HSC Regional Policy
PDF (507 KB)

NICE Clinical Guideline NG233 - Otitis media with effusion in under 12s (updates and replaces CG60)
PDF (514 KB)

NICE Clinical Guideline NG234 - Spinal metastases and metastatic spinal cord compression (updates and replaces CG75)
PDF (513 KB)

NICE Clinical Guideline NG235 - Intrapartum care (updates and replaces CG190)
PDF (565 KB)

NICE Clinical Guideline NG236 - Stroke rehabilitation in adults (updates and replaces CG162)
PDF (568 KB)

NICE Clinical Guideline NG238 - Cardiovascular disease: risk assessment and reduction, including lipid modification (updates and replaces CG181)
PDF (510 KB)

NICE Technology Appraisal TA755 - Risdiplam for treating spinal muscular atrophy (revised)
PDF (511 KB)

NICE Technology Appraisal TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (partial review)
PDF (696 KB)

NICE Technology Appraisal TA937 - Targeted-release budesonide for treating primary IgA nephropathy
PDF (512 KB)

NICE Technology Appraisal TA942 - Empagliflozin for treating chronic kidney disease
PDF (570 KB)

NICE Technology Appraisal TA943 - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
PDF (519 KB)

NICE Technology Appraisal TA944 - Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
PDF (512 KB)

NICE Technology Appraisal TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (review of TA693)
PDF (513 KB)

NICE Technology Appraisal TA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
PDF (512 KB)

NICE Technology Appraisal TA948 - Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
PDF (511 KB)

NICE Technology Appraisal TA949 - Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over
PDF (514 KB)

NICE Technology Appraisal TA950 - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over
PDF (511 KB)

NICE Technology Appraisal TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
PDF (513 KB)

NICE Technology Appraisal TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
PDF (514 KB)

NICE Technology Appraisal TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
PDF (513 KB)

Help viewing documents